AstraZeneca
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
AstraZeneca’s new antibiotic Zavicefta gets European approval for serious bacterial infections
June 29, 2016Research and Development, Sales and Marketing AstraZeneca, European Commission, Zavicefta, bacterial infections, regulation
UK drug firm AstraZeneca (LSE: AZN) said the European Commission has granted marketing authorisation for its Zavicefta (ceftazidime-avibactam), a new combination …
Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation
June 24, 2016Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …
AstraZeneca set to lose out on $80 million after US turns down flu vaccine
June 23, 2016Sales and Marketing AstraZeneca, CDC, flu, flu vaccine
AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …
Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC
June 20, 2016Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer
Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …
FDA issues warnings on Janssen, AstraZeneca diabetes drugs
June 15, 2016Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana
The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …
AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront
June 9, 2016Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement
UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
AstraZeneca says NDA for drug to treat hyperkalaemia gets observations from the US FDA
May 27, 2016Medical Communications, Research and Development AstraZeneca, NDA, US FDA, regulation
UK pharma firm AstraZeneca (LSE: AZN) on Friday said the US Food and Drug Administration (FDA) has issued a complete …
AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer
May 27, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, breast cancer, comparision study, drug trial
UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed …
Nice recommends three drugs to treat diabetes
May 25, 2016Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
China to cut prices of GSK, AstraZeneca drugs
May 23, 2016Sales and Marketing AstraZeneca, China, GSK, drug prices
Chinese health authorities have announced steps to cut the prices of three costly drugs in their latest attempt to reduce …
AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials
May 18, 2016Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III
AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial
May 17, 2016Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial
UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
